Home/Pipeline/SPB-20X1

SPB-20X1

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

SuperBranche

About SuperBranche

SuperBranche, founded in 2019 and based in Paris, is a private biotech company with a unique theranostic platform centered on its proprietary SUPERSPIO magnetic nanoparticles. The platform combines diagnostic imaging (MRI/MPI) with therapeutic capabilities (magnetic hyperthermia) for oncology, particularly aimed at tracking innovative cell therapies and treating solid tumors. The company is in the preclinical stage with its lead candidate, SPB-20X1, recently secured €13 million in funding, and is constructing a GMP pilot production facility in Sélestat, France. SuperBranche leverages open innovation through collaborations with research institutes and industrial partners.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed